Janssen files Simponi in US and EU for refractory ulcerative colitis
This article was originally published in Scrip
Executive Summary
Janssen (Johnson & Johnson) has filed for approval in the US and EU for its subcutaneous anti-TNF product Simponi (golimumab) for the additional indication of ulcerative colitis.